Shanghai JMT-Bio Inc. clinical trials
Acquired by CSPC Pharmaceutical Group Limited
The registry lists 42 studies whose lead sponsor is Shanghai JMT-Bio Inc.. 29 are recruiting or about to start. Per ClinicalTrials.gov, last updated Sep 25, 2026.
Where
- China
- 28
Registry sponsor names on this page
- Shanghai JMT-Bio Inc.42 studies
Something wrong with this grouping? Tell us on the CSPC Pharmaceutical Group Limited page.
Studies
Recruiting first, then most recently updated. Showing 42 of 42. All CSPC Pharmaceutical Group Limited studies →
- Evaluate the Safety and Tolerability of Multiple Doses of JMT206 Injection in Obese ParticipantsNot yet recruitingNCT07840729Phase 1
Sponsor listed in the registry: Shanghai JMT-Bio Inc. · Shanghai JMT-Bio Inc. — acquired company within the CSPC Pharmaceutical Group Limited group
- Phase I/II Clinical Study of JMT108 Injection for the Treatment of Advanced Malignant Melanoma and Urinary Tract TumorsRecruitingNCT07280832Phase 1/2
Sponsor listed in the registry: Shanghai JMT-Bio Inc. · Shanghai JMT-Bio Inc. — acquired company within the CSPC Pharmaceutical Group Limited group
- A Study of JMT203 in Patients With Cancer CachexiaRecruitingNCT06868849Phase 1/2
Sponsor listed in the registry: Shanghai JMT-Bio Inc. · Shanghai JMT-Bio Inc. — acquired company within the CSPC Pharmaceutical Group Limited group
- A Study of JSKN003 Versus Trastuzumab in Combination With Pertuzumab and Docetaxel as First-Line Treatment for HER2-Positive Recurrent or Metastatic Breast CancerNot yet recruitingNCT07545044Phase 2
Sponsor listed in the registry: Shanghai JMT-Bio Inc. · Shanghai JMT-Bio Inc. — acquired company within the CSPC Pharmaceutical Group Limited group
- A Phase III Study of KN026 in Combination With HB1801 as Adjuvant Therapy for Resectable HER2-Positive Breast CancerRecruitingNCT07441460Phase 3
Sponsor listed in the registry: Shanghai JMT-Bio Inc. · Shanghai JMT-Bio Inc. — acquired company within the CSPC Pharmaceutical Group Limited group
- SYS6090 Combination Therapy in Advanced Lung CancerNot yet recruitingNCT07472647Phase 1/2
Sponsor listed in the registry: Shanghai JMT-Bio Inc. · Shanghai JMT-Bio Inc. — acquired company within the CSPC Pharmaceutical Group Limited group
- Evaluate the Safety, Tolerability, PK, and PD of JMT206 Injection in Healthy ParticipantsRecruitingNCT07419698Phase 1
Sponsor listed in the registry: Shanghai JMT-Bio Inc. · Shanghai JMT-Bio Inc. — acquired company within the CSPC Pharmaceutical Group Limited group
- JSKN003 Versus Physician Choiced Treatment in Patients With HER2-positive and Advanced Colorectal Cancer Who Had Failed to Respond to Oxaliplatin, 5-Fu, and IrinotecanNot yet recruitingNCT07384377Phase 3
Sponsor listed in the registry: Shanghai JMT-Bio Inc. · Shanghai JMT-Bio Inc. — acquired company within the CSPC Pharmaceutical Group Limited group
- First-in-Human Investigation of JMT108 Injection in Participants With Advanced Malignant TumorsRecruitingNCT06877650Phase 1/2
Sponsor listed in the registry: Shanghai JMT-Bio Inc. · Shanghai JMT-Bio Inc. — acquired company within the CSPC Pharmaceutical Group Limited group
- A Study of KN026-based Combination Therapy in HER2-positive Gastric CancerNot yet recruitingNCT07332533Phase 2/3
Sponsor listed in the registry: Shanghai JMT-Bio Inc. · Shanghai JMT-Bio Inc. — acquired company within the CSPC Pharmaceutical Group Limited group
- a Phase 1b/2a Study of JMT202 Injection in Participants With HypertriglyceridemiaRecruitingNCT07140809Phase 1/2
Sponsor listed in the registry: Shanghai JMT-Bio Inc. · Shanghai JMT-Bio Inc. — acquired company within the CSPC Pharmaceutical Group Limited group
- JMT106 Injection in the Treatment of Advanced Solid TumorsRecruitingNCT07275073Phase 1
Sponsor listed in the registry: Shanghai JMT-Bio Inc. · Shanghai JMT-Bio Inc. — acquired company within the CSPC Pharmaceutical Group Limited group
- The Study of JMT101 Combined With Irinotecan as a ≥3rd-Line Treatment in Metastatic Colorectal CancerNot yet recruitingNCT07134205Phase 3
Sponsor listed in the registry: Shanghai JMT-Bio Inc. · Shanghai JMT-Bio Inc. — acquired company within the CSPC Pharmaceutical Group Limited group
- A Study to Learn More About the Effects and Safety of JMT601 in Adults With Primary Membranous NephropathyNot yet recruitingNCT07029139Phase 2
Sponsor listed in the registry: Shanghai JMT-Bio Inc. · Shanghai JMT-Bio Inc. — acquired company within the CSPC Pharmaceutical Group Limited group
- JSKN003 Combined Treatment of HER2-positive Gastric CancerNot yet recruitingNCT06998771Phase 2
Sponsor listed in the registry: Shanghai JMT-Bio Inc. · Shanghai JMT-Bio Inc. — acquired company within the CSPC Pharmaceutical Group Limited group
- Efficacy and Safety of KN026 in Combination With HB1801 in the First-line Treatment of Subjects With HER2-positive Recurrent or Metastatic Breast Cancer.RecruitingNCT05838066Phase 3
Sponsor listed in the registry: Shanghai JMT-Bio Inc. · Shanghai JMT-Bio Inc. — acquired company within the CSPC Pharmaceutical Group Limited group
- A Study to Evaluate the Efficacy and Safety of Glumetinib Combined With Osimertinib Mesylate Versus Platinum-based Doublet Chemotherapy in Non-Small Cell Lung Cancer Patients After Resistance to EGFR-TKIsRecruitingNCT06829459Phase 3
Sponsor listed in the registry: Shanghai JMT-Bio Inc. · Shanghai JMT-Bio Inc. — acquired company within the CSPC Pharmaceutical Group Limited group
- Glumetinib Combined With Osimertinib Treatment for Non-Small Cell Lung Cancer PatientsNot yet recruitingNCT06908772Phase 2/3
Sponsor listed in the registry: Shanghai JMT-Bio Inc. · Shanghai JMT-Bio Inc. — acquired company within the CSPC Pharmaceutical Group Limited group
- JMT101 Combined With Mitoxantrone Liposome for Nasopharyngeal CancerNot yet recruitingNCT06892431Phase 2
Sponsor listed in the registry: Shanghai JMT-Bio Inc. · Shanghai JMT-Bio Inc. — acquired company within the CSPC Pharmaceutical Group Limited group
- JSKN003 Versus Trastuzumab Emtansine (T-DM1) for HER2-Positive, Advanced Breast CancerRecruitingNCT06846437Phase 3
Sponsor listed in the registry: Shanghai JMT-Bio Inc. · Shanghai JMT-Bio Inc. — acquired company within the CSPC Pharmaceutical Group Limited group
- A Clinical Study of JMT101 in Combination With Osimertinib Versus Osimertinib Alone as First-Line Treatment for Patients With Locally Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC) Harboring Epidermal Growth Factor Receptor (EGFR) Sensitive MutationsRecruitingNCT06735391Phase 3
Sponsor listed in the registry: Shanghai JMT-Bio Inc. · Shanghai JMT-Bio Inc. — acquired company within the CSPC Pharmaceutical Group Limited group
- A Study of JMT601 in Participants With Relapsed or Refractory CD20-positive B-cell Non-Hodgkin LymphomaRecruitingNCT06725524Phase 1
Sponsor listed in the registry: Shanghai JMT-Bio Inc. · Shanghai JMT-Bio Inc. — acquired company within the CSPC Pharmaceutical Group Limited group
- A Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of JMT202Enrolling by invitationNCT06564467Phase 1
Sponsor listed in the registry: Shanghai JMT-Bio Inc. · Shanghai JMT-Bio Inc. — acquired company within the CSPC Pharmaceutical Group Limited group
- JMT101 in Combination With Osimertinib, Versus Cisplatin-pemetrexed in Participants With Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) Characterized by Epithermal Growth Factor Receptor (EGFR) Exon 20ins MutationsNot yet recruitingNCT06380348Phase 3
Sponsor listed in the registry: Shanghai JMT-Bio Inc. · Shanghai JMT-Bio Inc. — acquired company within the CSPC Pharmaceutical Group Limited group
- Efficacy and Safety of JMT101 Combined Wth Docetaxel / HB1801 in Patients With Squamous Cell Non-Small Cell Lung CancerNot yet recruitingNCT06319313Phase 2/3
Sponsor listed in the registry: Shanghai JMT-Bio Inc. · Shanghai JMT-Bio Inc. — acquired company within the CSPC Pharmaceutical Group Limited group
- A Study to Assess the Prevention of Bone-related Events in Patients With Bone Metastases From Malignant Solid Tumors Treated With JMT103 Compared to Zoledronic AcidNot yet recruitingNCT06221072Phase 3
Sponsor listed in the registry: Shanghai JMT-Bio Inc. · Shanghai JMT-Bio Inc. — acquired company within the CSPC Pharmaceutical Group Limited group
- KN026 in Combination With Chemotherapy in HER2 Positive Gastric Cancer Subjects Who Have Failed First-line TherapyRecruitingNCT05427383Phase 2/3
Sponsor listed in the registry: Shanghai JMT-Bio Inc. · Shanghai JMT-Bio Inc. — acquired company within the CSPC Pharmaceutical Group Limited group
- A Study of JMT101 in Patients With Metastatic Colorectal CancerNot yet recruitingNCT06089330Phase 2
Sponsor listed in the registry: Shanghai JMT-Bio Inc. · Shanghai JMT-Bio Inc. — acquired company within the CSPC Pharmaceutical Group Limited group
- A Study to Evaluate the Efficacy and Safety of Narlumosbart (JMT103) in Patients With Giant Cell Tumor of BoneNot yet recruitingNCT05813665Phase 3
Sponsor listed in the registry: Shanghai JMT-Bio Inc. · Shanghai JMT-Bio Inc. — acquired company within the CSPC Pharmaceutical Group Limited group
- A Clinical Trial to Assess the Efficacy and Safety of JMT103 in Patients With Refractory HCMTerminatedNCT04198480Phase 1/2
Sponsor listed in the registry: Shanghai JMT-Bio Inc. · Shanghai JMT-Bio Inc. — acquired company within the CSPC Pharmaceutical Group Limited group
- A Phase III Study of KN026 in Combination With HB1801 ± Carboplatin as Neoadjuvant Treatment for Early or Locally Advanced HER2-Positive Breast CancerActive, not recruitingNCT06747338Phase 3
Sponsor listed in the registry: Shanghai JMT-Bio Inc. · Shanghai JMT-Bio Inc. — acquired company within the CSPC Pharmaceutical Group Limited group
- JMT101 Combined With Osimertinib in Patients With Stage Ⅲb-Ⅳ Non-small Cell Lung Cancer (NSCLC) Characterized by Epithermal Growth Factor Receptor (EGFR) Common MutationsActive, not recruitingNCT06391944Phase 2
Sponsor listed in the registry: Shanghai JMT-Bio Inc. · Shanghai JMT-Bio Inc. — acquired company within the CSPC Pharmaceutical Group Limited group
- Efficacy and Safety of JMT103 in Patients With Bone Metastases From Solid TumorsCompletedNCT04630522Phase 1
Sponsor listed in the registry: Shanghai JMT-Bio Inc. · Shanghai JMT-Bio Inc. — acquired company within the CSPC Pharmaceutical Group Limited group
- Efficacy and Safety of JMT103 in Patients With Giant Cell Tumor of BoneStatus unknownNCT04255576Phase 1/2
Sponsor listed in the registry: Shanghai JMT-Bio Inc. · Shanghai JMT-Bio Inc. — acquired company within the CSPC Pharmaceutical Group Limited group
- Real-World Effectiveness of Osimertinib for Patients With Non-Small Cell Lung CancerStatus unknownNCT05513664
Sponsor listed in the registry: Shanghai JMT-Bio Inc. · Shanghai JMT-Bio Inc. — acquired company within the CSPC Pharmaceutical Group Limited group
- Efficacy and Safety of JMT103 in the Treatment of Postmenopausal Women With OsteoporosisStatus unknownNCT05278338Phase 2
Sponsor listed in the registry: Shanghai JMT-Bio Inc. · Shanghai JMT-Bio Inc. — acquired company within the CSPC Pharmaceutical Group Limited group
- A Real-world Study on Patients of Unresectable Giant Cell Tumor of BoneCompletedNCT05402865
Sponsor listed in the registry: Shanghai JMT-Bio Inc. · Shanghai JMT-Bio Inc. — acquired company within the CSPC Pharmaceutical Group Limited group
- Efficacy and Safety of JMT103 in the Treatment of Glucocorticoid Induced OsteoporosisStatus unknownNCT05397938Phase 2
Sponsor listed in the registry: Shanghai JMT-Bio Inc. · Shanghai JMT-Bio Inc. — acquired company within the CSPC Pharmaceutical Group Limited group
- Efficacy and Safety of JMT101 Combined With Osimertinib in Patients With Non-Small Cell Lung CancerStatus unknownNCT05132777Phase 2
Sponsor listed in the registry: Shanghai JMT-Bio Inc. · Shanghai JMT-Bio Inc. — acquired company within the CSPC Pharmaceutical Group Limited group
- Efficacy and Safety of JMT101 in Patients With Advanced Solid TumorStatus unknownNCT04689100Phase 1
Sponsor listed in the registry: Shanghai JMT-Bio Inc. · Shanghai JMT-Bio Inc. — acquired company within the CSPC Pharmaceutical Group Limited group
- Efficacy and Safety of JMT101 Combined With Afatinib (or Osimertinib) in Patients With Non-Small Cell Lung CancerStatus unknownNCT04448379Phase 1
Sponsor listed in the registry: Shanghai JMT-Bio Inc. · Shanghai JMT-Bio Inc. — acquired company within the CSPC Pharmaceutical Group Limited group
- Safety, Tolerability and PK/PD of JMT103 in Patients With Bone Metastases From TumorsStatus unknownNCT03550508Phase 1
Sponsor listed in the registry: Shanghai JMT-Bio Inc. · Shanghai JMT-Bio Inc. — acquired company within the CSPC Pharmaceutical Group Limited group